With the approval of Thymoglobulin, the second major piece of its transplant package, and expected approval of its cyclosporine in Europe, SangStat Medical Corp. believes it has the critical mass to attain significant growth and profitability over the next five years.

But no sooner does a company get one or two products under its belt than investors start looking at what comes next. Down the road, the company plans to fuel growth with products in additional transplant areas such as liver, tissue and bone marrow transplant and possibly with additional product acquisitions.